Finanzen von Roivant Sciences Ltd (ROIV)ROIVRoivant Sciences Ltd

Evaluating the bottom line, Roivant Sciences Ltd maintains a gross margin of 80.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -22460.82%, while the net margin is -20152.98%. These profitability ratios, combined with a Return on Equity (ROE) of -6.21%, provide a clear picture of how effectively ROIV converts its operational activities into shareholder value.

In the context of the broader market, ROIV competes directly with industry leaders such as INCY and VTRS. With a market capitalization of $25.60B, it holds a leading position in the sector. When comparing efficiency, ROIV's gross margin of 80.31% stands against INCY's 93.73% and VTRS's 42.03%. Such benchmarking helps identify whether Roivant Sciences Ltd is trading at a premium or discount relative to its financial performance.

Roivant has shown fluctuating revenues, with a total revenue of 2.52 million USD in Q4 2026, but it also reported a significant net income loss of -265.89 million USD in the same quarter. The gross margin has varied, with a recent figure of 87.30%, indicating potential for profitability if revenues increase.